A global network of experts in the field of RSV infections, combining the knowledge and capacity required to enhance development of novel RSV therapeutics
RESVINET - RSV

ReSViNET was founded in Utrecht, The Netherlands on January 14th, 2014 by 9 clinician scientists and Julius Clinical, an Academic Research Organization, as a fully independent research network.

Our **Vision** is to combine scientific expertise and leadership to decrease the global burden of RSV infection.

Our **Mission** is to perform high quality research to enhance knowledge of RSV epidemiology and develop safe and effective therapeutic and preventive interventions.

RSV - BACKGROUND

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children worldwide. RSV infections occur mostly in yearly epidemic outbreaks. It is highly contagious and spreads through droplets upon coughing or sneezing.

Approximately 33.8 million episodes of RSV-associated lower respiratory infections occur in children worldwide every year. RSV infection causes a worldwide burden of morbidity and mortality and has been presented as the second main cause of death during infancy. It is estimated that 33,000 to 199,000 RSV-related deaths happen per year, of which 99% occur in developing countries. In Europe and the US, on average 1% of children in their 1st year of life are hospitalised with a severe infection.

In Europe, RSV accounts for 42-45% of hospital admissions for lower respiratory tract infections in children under 2. In addition to being a severe acute disease, RSV infection has been linked to an increased risk of the development of asthma in later life.

RSV - EXISTING PROBLEMS

RSV is a complex public health problem. The level of clinical, industrial and public interest is only becoming proportionate to the magnitude of the problem. There are currently no vaccine approaches and prophylaxis is limited to passive immunisation with palivizumab.

An unmet need exists for both (i) long-term development strategies for vaccine and immunoprophylaxis candidates against RSV and (ii) biosimilars that can replace off-patent palivizumab on the short-term.

Although the recent increase in industrial activity in development of RSV therapeutics is apparent, concerted and timely solutions to the medical needs are not yet in sight. Key research questions can only be answered through multidisciplinary and networking approaches. ReSViNET is the first and the only international, integrated, multidisciplinary and translational research approach focused on RSV infections.

SHARING KNOWLEDGE

Publishing Position Papers and scientific manuscripts:

- "Development and Validation of a New Clinical Scale for Infants with Acute Respiratory Infection: The ReSVinet Scale" PLOS ONE 2016
- "Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics" Lancet Respiratory Medicine 2015
- "RSV—Still More Questions Than Answers" The Pediatric Infectious Disease Journal 2014

THE RESVINET SCALE

A new clinical scale for infants with acute respiratory infection

Our board member Dr. Federico Martinón Torres and his team designed a new clinical scale for infants with acute respiratory infection, the ReSVinet scale.

The ReSVinet scale is based on seven parameters – feeding intolerance, medical intervention, respiratory difficulty, respiratory frequency, apnoea, general condition, fever – that were assigned different values (from 0 to 3) for a total of 20 points. 170 children under two years of age with ARI were assessed independently by three paediatricians using this scale.

We invite you to read the full report by downloading the file via the link on our website: www.resvinet.org
OUR GLOBAL REACH

Our Board Members are located around the globe. RSV is a cyclical illness, and our global network ensures that trials can be conducted year round, following the outbreak of the disease across continents and hemispheres. We deliver our services for clinical trials in Pediatrics as well as for trials in older adults.

OUR GOALS

- **COMBINE** the knowledge and capacity required to enhance development of novel RSV therapeutics.
- **ADVOCATE** and create awareness for the RSV disease.
- **STIMULATE** and perform cutting-edge research, with a focus on randomized clinical trials.
- **PROMOTE** appropriate allocation of resources for RSV related research and introduction of prevention and treatment strategies for better care for patients with RSV infection.
- **ACT** as a focal point for effective partnerships with stakeholders with the ultimate aim of reducing global child morbidity and mortality.

WHY WORK WITH RESVINET?

- ReSViNET has well-trained research professionals
- ReSViNET sites are academic hospitals with many years of experience in research
- ReSViNET works with Standard Operating Procedures (SOPs)
- ReSViNET stands for Good Clinical Practice (GCP)
- ReSViNET works with one contract for over 50 sites
- ReSViNET has a high recruitment rate through shared competition between the sites
- ReSViNET has an above-average retention rate
- ReSViNET sites work together to promote recruitment and quality in research

WE OFFER YOU

A Peer-to-peer Leadership Model

ReSViNET board members are experts in the field of RSV infection, pathophysiology and epidemiology and are known to be skilled recruiters. Together they have designed and completed a multitude of RSV trials. They have significant experience in recruitment and retention strategies mitigating risks of delays.

We provide a model infusing scientific leadership, RSV knowledge and trial experience into various levels of complex clinical trials for the benefit of trial outcomes, offering academic leadership and leveraging our RSV knowledge and experience towards the site study team.
Below is a sampling of the hospitals, clinics and universities where our Board Members are located and affiliated with active sites.

ACCESS TO PATIENTS

Total # beds: 10,477
Total # PICU/ICU beds: 510

RESVINET MEETINGS AND CONFERENCES

ReSViNET meetings and conferences are devoted exclusively to RSV infection prevention and treatment. They focus on the scientific developments and demands in RSV field.

We aim to bring together the scientific data and expertise, connecting different stakeholders involved in RSV research e.g. Scientists, policy makers and Pharmaceutical companies and stimulating discussions regarding the opportunities for future international collaboration and achievement in our field.
STRATEGIC RSV INTERVENTION DEVELOPMENT ENTITY

- STRIDE, a highly interactive and collaborating entity

- Realizing accelerated preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases

- Offering more value to clients by combining expertise into integrated project teams

- Covering all R&D activities that will bring novel ideas for RSV intervention strategies

- Integrated way bringing basic scientific discoveries, via preclinical and clinical studies to clinical use.

CONTACT US

LOUIS BONT, PROF. DR.
Chairman
louis.bont@resvinet.org

LEYLA Kragten-Tabatabaie, PHD
Scientific Network Manager
leyla.kragten@juliusclinical.com